| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,700 | ₹6.1 0% | 4,5000% |
| 1250% | ₹1,060.3 0% | 4,800 | ₹4.6 -30.82% | 8,25013.79% |
| 7500% | ₹749.95 0% | 4,900 | ₹6 0% | 5,7500% |
| 1250% | ₹811.85 0% | 5,000 | ₹6.9 -40.25% | 23,625-0.52% |
| - | - | 5,100 | ₹20.2 0% | 9,6250% |
| 1250% | ₹489.25 0% | 5,200 | ₹24 0% | 6250% |
| - | - | 5,250 | ₹29.8 0% | 2,2500% |
| 6250% | ₹366.25 0% | 5,300 | ₹20.5 -44.14% | 19,625-6.54% |
| 3750% | ₹295.55 -1.72% | 5,350 | ₹33.05 27.6% | 5,000166.66% |
| 1,0000% | ₹289.4 0% | 5,400 | ₹33.85 -43.15% | 14,62521.87% |
| 5000% | ₹278.8 0% | 5,450 | ₹41.1 -56.5% | 3,1251150% |
| 4,7500% | ₹287.55 25.95% | 5,500 | ₹53 -31.87% | 21,250-0.58% |
| 1,6250% | ₹269.65 33.39% | 5,550 | ₹127.65 0% | 4,2500% |
| 4,5002.85% | ₹223.2 25.28% | 5,600 | ₹79 -32.13% | 4,62560.86% |
| 7,000-41.05% | ₹223.1 45.86% | 5,650 | ₹90.7 -39.53% | 9,125-33.63% |
| 18,375-6.36% | ₹180.55 40.28% | 5,700 | ₹113.15 -31.54% | 13,0001.96% |
| 4,0003.22% | ₹157.35 46.37% | 5,750 | ₹333.45 0% | 1250% |
| 25,25029.48% | ₹129.8 46.5% | 5,800 | ₹164.25 -25.42% | 13,500-2.70% |
| 1,87515.38% | ₹108 34.16% | 5,850 | ₹295.75 0% | 3750% |
| 12,625102% | ₹93 68.47% | 5,900 | ₹229.65 -24.88% | 1,625333.33% |
| 1,8750% | ₹40.2 0% | 5,950 | ₹339.6 0.45% | 6250% |
| 26,875-23.75% | ₹62 60% | 6,000 | ₹285.25 -18.36% | 625400% |
| 9,3752.73% | ₹52.8 10.8% | 6,050 | ₹569.2 0% | 2,0000% |
| 12,250600% | ₹40.2 43.57% | 6,100 | ₹618.55 0% | 8750% |
| 6,500642.85% | ₹34.95 -3.98% | 6,150 | - | - |
| 17,75010.93% | ₹27.45 66.36% | 6,200 | - | - |
| 2,000100% | ₹22.35 31.47% | 6,250 | - | - |
| 1,500-36.84% | ₹17.9 24.3% | 6,300 | - | - |
| - | - | 6,350 | ₹939.55 0% | 3750% |
| 4,6250% | ₹16.8 20% | 6,400 | ₹720 0% | 1250% |
| 6,1256.52% | ₹6.4 23.07% | 6,500 | ₹791.1 0% | 3750% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
